Stevanato Group has beaten earnings estimates in 3 of the last 4 quarters with consistent 5-10% upside surprises and analyst targets implying 28% price upside, but the stock is in a confirmed downtrend with a death cross and free cash flow that is negative 40% relative to net income, creating a gap between earnings quality and analyst optimism.
Thesis pillars
- Earnings Beat Analyst Upside↑Improving
- Death Cross Confirmed Downtrend↓Deteriorating
- Fcf Earnings Quality Divergence→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026· older than 90 days
Stevanato Group S.p.A. (STVN) Stock Analysis
Oversold Bounce setup
Healthcare · Medical Instruments & Supplies
Hold if already holding. Not a fresh buy at $14.10, but acceptable to hold if already in. Reasons: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.5); Weak growth.
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two... Read more
Hold if already holding. Not a fresh buy at $14.10, but acceptable to hold if already in. Reasons: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.5); Weak growth. Chart setup: Oversold RSI 24, near Bollinger lower, volume surge. Multiple concerning factors. Consider reducing position. | News modifier +1 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Score 5.0/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
Recent developments
updated Oct 28, 2026Recent Developments — Stevanato Group S.p.A.
Latest news
- NEWS Stevanato Group S.p.A. (STVN) Rallies on 2Q26 Revenue Growth and EBITDA Margin Expansion - Yahoo Finance — Yahoo Finance Oct 28, 2026 positive
- NEWS Stevanato Group S.p.A. $STVN Stock Acquired by Schwartz Investment Counsel Inc. - MarketBeat — MarketBeat Oct 28, 2026 neutral
- NEWS Stevanato Group partners with Aptar for syringe testing By Investing.com - Investing.com Nigeria — Investing.com Nigeria Oct 27, 2026 positive
- NEWS Stevanato Group partners with Aptar for syringe testing By Investing.com - Investing.com India — Investing.com India Oct 27, 2026 positive
- NEWS Stevanato Group and Aptar Pharma Collaborate to Help Accelerate Pre-Filled Syringe System Selection - www.marketscreener — www.marketscreener.com Oct 27, 2026 positive
Latest item Oct 28, 2026 · Generated 2026-11-04T12:04:37Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $14.10, but acceptable to hold if already in. Reasons: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.5); Weak growth. Chart setup: Oversold RSI 24, near Bollinger lower, volume surge. Multiple concerning factors. Consider reducing position. | News modifier +1 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Analyst target $21.61 (+53.3%), stop $13.11 (−7.6%), A.R:R 3.5:1. Score 5.0/10, moderate confidence.
Analyst target: $21.61 (+53.3% upside). Analyst target $21.61 (+53.3%), stop $13.11 (−7.6%), A.R:R 3.5:1. Stop-loss: $13.11.
V7 low-quality RISK_OFF penalty: -0.5 (Q=4.5); Weak growth; Negative momentum.
Stevanato Group S.p.A. trades at a P/E of 17.6 (forward 17.1). TrendMatrix value score: 6.0/10. Verdict: Hold.
19 analysts rate STVN, with a consensus score of 4.1/5. 12 analysts publish price targets averaging $25.
What does Stevanato Group S.p.A. do?Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide...
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass converting machines; and after-sales services, such as line optimization and line conversions, training, logistics, spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug products, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.